歌礼制药(01672.HK)澄清未参与旗下产品武汉肺炎应用研究
针对有报道指旗下产品利托那韦(Ritonavir)及ASC09复方片可用於相关治疗武汉新型冠状病毒肺炎疫情,歌礼制药(01672.HK)澄清指,该等报道的结论是根据中国科学院武汉病毒研究所与军事医学科学院毒物研究所联合研究成果作出,强调公司并未参与相关科研过程,亦未提供相关药物供其研究。
公司又表示,利托那韦及ASC09复方片均为本公司尚未获得上市批文的产品,已於2020年1月25日向国家药品监督管理局及其药品审评中心申请将利托那韦及ASC09复方片纳入国家应急通道,在做出该等申请时并不知晓上述的联合研究成果,截至目前暂未收到相关确认,将会与相关药监部门积极配合,并就该等申请的任何进展及时告知公众。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.